Announcements Trials
Browse Landscape

Phase

Phase 1 51Phase 2 50Phase 1/2 32Phase 3 5Phase EARLY_PHASE1 2Phase NA 1Phase 2/3 1

Status

Recruiting 2Not yet recruiting 2Completed 2Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 13Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 9Prostatic Neoplasms 7Recurrence 6Neoplasm Metastasis 6Head and Neck Neoplasms 6Carcinoma, Hepatocellular 6Stomach Neoplasms 5Pancreatic Neoplasms 5Colorectal Neoplasms 5Carcinoma, Squamous Cell 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Melanoma 4Liver Neoplasms 4Endometrial Neoplasms 4Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Hematologic Neoplasms 3Fatigue 3Esophageal Neoplasms 3Depression 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Rectal Neoplasms 2

Interventions

eryaspase 1Gemcitabine 1Erythrocyte Count 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Terminated × Triple Negative Breast Neoplasms × Clear all
NCT03674242 2022-08-01

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)

ERYtech Pharma

Phase 2/3 Terminated
27 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡